FDA ex­pert pan­el lines up 19-to-1 against Pfiz­er’s os­teoarthri­tis drug tanezum­ab

Out­side ex­perts ad­vis­ing the FDA vot­ed 19 to 1 against Pfiz­er’s po­ten­tial os­teoarthri­tis drug tanezum­ab, say­ing the pro­posed risk eval­u­a­tion and mit­i­ga­tion strat­e­gy (REMS) will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER